Aktis Oncology to Present at the BofA Securities Health Care Conference
Rhea-AI Summary
Aktis Oncology (NASDAQ:AKTS) will present at the BofA Securities Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 10:00 a.m. PT.
Matthew Roden, Ph.D., President and CEO, will deliver the presentation. A live webcast and an archived replay (available ~90 days) will be accessible via the Investors section of the Aktis website.
Positive
- None.
Negative
- None.
News Market Reaction – AKTS
In the May 6 session, AKTS gained 3.03%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 03 | Peer M&A mention | Neutral | -2.2% | Third-party acquisition where Aktis is cited for its IPO track record. |
| Apr 21 | Clinical data update | Positive | +6.8% | Announcement of first clinical imaging and dosimetry data for AKY-2519 at ASCO. |
| Apr 16 | Board appointment | Positive | +2.8% | Appointment of experienced R&D leader Glenn Gormley and creation of science committee. |
| Mar 30 | FDA and earnings | Positive | +8.2% | FDA IND clearances, full-year 2025 results, and detailed pipeline and cash updates. |
| Feb 24 | Investor conferences | Neutral | -2.5% | CEO presentations at two March investor conferences with webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive R&D and financial milestones have recently coincided with favorable price reactions, while general news and third-party items have seen mixed or negative moves.
Over recent months, Aktis has highlighted major R&D and financing milestones, including FDA clearance of INDs and full-year 2025 results on Mar 30, 2026, which saw the stock gain 8.16%. Clinical data and ASCO presentation plans on Apr 21, 2026 and a board appointment on Apr 16, 2026 also drew positive reactions. More routine items, such as March investor conferences and a peer-focused M&A announcement mentioning Aktis’ IPO, saw modest declines, underscoring that investors have responded most positively to clear pipeline and funding progress.
Key Terms
targeted radiopharmaceuticals medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the BofA Securities Health Care Conference in Las Vegas, Nevada. The presentation will take place on Wednesday, May 13, 2026, at 10:00 a.m. PT.
A live webcast of the presentations may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.
About Aktis’ miniprotein radioconjugate platform
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anti-cancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.
About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most advanced clinical-stage pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second clinical-stage pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung, colorectal, and other solid tumors. Aktis has a discovery collaboration with Eli Lilly and Company to leverage Aktis’ miniprotein platform to develop novel radioconjugates outside of its proprietary pipeline. For more information, please visit www.aktisoncology.com.
Media contact:
Melone Communications, LLC
Liz Melone
617-256-6622
liz@melonecomm.com
Investor contact:
Precision AQ
Alex Lobo
212-698-8802
Alex.lobo@precisionaq.com
